FR Doc E9-4271[Federal Register: March 2, 2009 (Volume 74, Number 39)]
[Notices] [Page 9107-9108] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02mr09-51]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall, prior to issuing a registration
under this section to a bulk manufacturer of a controlled substance in schedule
I or II, and prior to issuing a registration under 21
U.S.C. 952(a)(2), authorizing the importation of such a substance, provide
manufacturers holding registrations for the bulk manufacture of the substance an
opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations 1301.34(a),
this is notice that on December 22, 2008, Sigma Aldrich Manufacturing LLC., 3500
Dekalb Street, St. Louis, Missouri 63118, has made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as an importer of the
basic classes of controlled substances listed in schedule I and II:
|
Drug
|
Schedule
|
|
Cathinone (1235)
|
I
|
|
Methcathinone (1237)
|
I
|
|
Aminorex (1585)
|
I
|
|
Gamma Hydroxybutyric Acid (2010)
|
I
|
|
Methaqualone (2565)
|
I
|
|
Alpha-ethyltryptamine (7249)
|
I
|
|
Ibogaine (7260)
|
I
|
|
Lysergic acid diethylamide (7315)
|
I
|
|
Marihuana (7360)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Mescaline (7381)
|
I
|
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
|
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)
|
I
|
|
3,4-Methylenedioxy-N-ethylamphetamine (7404)
|
I
|
|
3,4-Methylenedioxymethamphetamine (MDMA) (7405)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Bufotenine (7433)
|
I
|
|
Diethyltryptamine (7434)
|
I
|
|
Dimethyltryptamine (7435)
|
I
|
|
Psilocybin (7437)
|
I
|
|
Psilocyn (7438)
|
I
|
|
1-[1-(2-Thienyl)cyclohexyl]piperdine (7470)
|
I
|
|
N-Benzylpiperazine (BZP) (7493)
|
I
|
|
Heroin (9200)
|
I
|
|
Normorphine (9313)
|
I
|
|
Etonitazene (9624)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Methylphenidate (1724)
|
II
|
|
Amobarbital (2125)
|
II
|
|
Pentobarbital (2270)
|
II
|
|
Secobarbital (2315)
|
II
|
|
Glutethimide (2550)
|
II
|
|
Nabilone (7379)
|
II
|
|
Phencyclidine (7471)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Diprenorphine (9058)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Diphenoxylate (9170)
|
II
|
|
Ecgonine (9180)
|
II
|
|
Ethylmorphine (9190)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Levorphanol (9220)
|
II
|
|
Meperidine (9230)
|
II
|
|
Methadone (9250)
|
II
|
|
Morphine (9300)
|
II
|
|
Thebaine (9333)
|
II
|
|
Opium powdered (9639)
|
II
|
|
Levo-alphacetylmethadol (9648)
|
II
|
|
Oxymorphone (9652)
|
II
|
|
Fentanyl (9801)
|
II
|
The company plans to import the listed controlled substances for sale to
research facilities for drug testing and analysis.
Any bulk manufacturer who is presently, or is applying to be, registered with
DEA to manufacture such basic classes of controlled substances may file comments
or objections to the issuance of the proposed registration and may, at the same
time, file a written request for a hearing on such application pursuant to 21
CFR 1301.43, and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections should be addressed, in quintuplicate,
[[Page 9108]]
to the Drug Enforcement Administration, Office of Diversion Control, Federal
Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia
22152; and must be filed no later than April 1, 2009.
This procedure is to be conducted simultaneously with, and independent of,
the procedures described in 21 CFR Sec. 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in the Federal Register on September 23,
1975, (40 FR 43745-46), all applicants for registration to import the basic
class of any controlled substance in schedule I or II are, and will continue to
be, required to demonstrate to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21
U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: February 23, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-4271 Filed 2-27-09; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).